Atossa Genetics (NASDAQ:ATOS) Earns Buy Rating from Maxim Group

Maxim Group restated their buy rating on shares of Atossa Genetics (NASDAQ:ATOS) in a research report report published on Friday morning, reports. The firm currently has a $8.00 price objective on the stock.

Separately, Ascendiant Capital Markets began coverage on Atossa Genetics in a report on Thursday. They issued a buy rating and a $7.00 price objective for the company.

Shares of NASDAQ ATOS opened at $2.44 on Friday. The stock’s 50-day simple moving average is $3.04 and its two-hundred day simple moving average is $2.53. Atossa Genetics has a twelve month low of $0.75 and a twelve month high of $5.08.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.15).

About Atossa Genetics

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

See Also: How does equity income fit into an investing strategy?

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.